RARE-X logo

Travere Therapeutics Reports Second Quarter 2021 Financial Results

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2021 financial results and provided a corporate update.

Read the full press release >
Rare Revolution Magazine Summer 2021 Cover

Rare Revolution Magazine’s Releases Issue Focused on Diversity, Equity & Inclusion in Rare Disease

July 26, 2021 -- Today, Rare Revolution Magazine launched its summer issue dedicated to diversity, equity and inclusion in rare disease. The issue explores ways that rare disease patient advocacy organizations, individuals and industry are working to advance health equity. Articles include conversations with members of the rare community about race, gender, sexual identity, age bias, access to clinical trials and therapy. Travere is proud to collaborate with Rare Revolution Magazine on this issue. Read the issue >

Stuart

,
Ten years after being diagnosed with IgA nephropathy, a rare kidney disease, Stuart’s kidney function had depleted significantly. Today, after a lifesaving kidney donation from his wife, Stuart gives back to the kidney community through advocacy

In the News: Our president and CEO Eric Dube featured in Life Science Leader Magazine

July 1, 2021 -- In its July issue published today, Life Science Leader Magazine featured our president and CEO Eric Dube. The feature piece, “How a First-Time CEO Transformed Retrophin Into Travere Therapeutics”, highlights Eric’s inspirational leadership journey, why Eric decided to join the company, his first 100 days as a new CEO, and the company’s transition from Retrophin to Travere Therapeutics. Read the article >
RARE-X logo

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in August 2021.

Read the full press release >
RARE-X logo

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS).

Read the full press release >

Chris

,
Chris was just a teenager when he was diagnosed with a rare genetic condition called cystinuria, which causes cystine kidney stones that often require surgery to remove.

Cheers to the Rare Moms on Mother’s Day

One year ago - Mother’s Day 2020, I was two and a half months away from meeting my third and final baby girl. 2020 was a tough year for everyone with the COVID pandemic and living our new normal, but it was about to hit a peak for me when I got news just a month later I would have never fathomed. Read a message from Valarie, baby Delila's mom
RARE-X logo

Travere Therapeutics Reports First Quarter 2021 Financial Results

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2021 financial results and provided a corporate update.

Read the full press release >

Tiffany

,
Managing a diagnosis of FSGS that came during COVID-19